Lecanemab is a monoclonal antibody with high affinity to amyloid-beta soluble protofibrils. It was approved in 2023 as an IV ...

Differences in outcomes between patients with early Alzheimer’s disease who used lecanemab and matched controls increased ...

Four years of lecanemab treatment led to less cognitive decline and potentially even improvement in clinical scores over time, with a favorable safety profile, in the open-label extension trial.

From taking HRT to eating a healthy diet, Kate Muir shares some of the precautionary measures she's trying to avoid ...

What the science says about lecanemab On Friday, the FDA’s Peripheral and Central Nervous System Drugs Advisory Committee met to discuss the results from a confirmatory Phase 3 study on ...

Lecanemab and donanemab effects lasting over three years, new treatments, trials of home injections and blood tests for ...

Experts have hailed the lecanemab as 'beginning of the end' for Alzheimer's after the drug was found to slow cognitive decline by more than a quarter in clinical trials in America, Europe and Asia.

The FDA’s accelerated approval of lecanemab was expected, said Dr. Richard Isaacson, director of the Alzheimer’s Prevention Clinic in the Center for Brain Health at Florida Atlantic University ...

But lecanemab’s quest for approval has been shadowed by the previous approval of another Alzheimer’s drug to get accelerated approval: aducanemab, sold as Aduhelm. During aducanemab’s ...

Lecanemab is a humanized immunoglobulin gamma 1 (IgG1) monoclonal antibody directed against aggregated soluble (protofibril) and insoluble forms of amyloid-beta (Aβ).

Lecanemab represents a major rebound for Biogen after Aduhelm — the company’s previous try at an Alzheimer’s treatment — failed when brought to market in 2021, the New York Times reported.

Lecanemab, a monoclonal antibody sold under the brand name Leqembi, is one of the first dementia drugs that appears to slow the progression of cognitive decline. The drug is not a cure but works ...